Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Rhea-AI Summary
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET. A live webcast will be available via the Investors & Media section of the company's website, and a replay will be posted approximately 48 hours after the event. Telephone participants must register to receive dial-in details and a unique passcode.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
KNSA gained 2.7% while peers showed mixed moves: BHC up 8.41%, HCM modestly higher, SUPN, INDV, and ALVO slightly lower. This pattern suggests today’s action was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Corporate update | Positive | -3.6% | Unaudited 2025 ARCALYST revenue, 62% growth and higher 2026 guidance. |
| Jan 07 | Conference appearance | Neutral | -1.6% | Planned presentation at J.P. Morgan Healthcare Conference with webcast access. |
| Nov 12 | Conference appearance | Neutral | -0.7% | Jefferies Global Healthcare Conference presentation and webcast logistics. |
| Oct 28 | Earnings results | Positive | -2.9% | Q3 2025 beat with 61% ARCALYST growth, raised 2025 guidance and positive net income. |
| Oct 23 | Earnings date set | Neutral | +0.4% | Announcement of Q3 2025 results date and webcast details. |
Recent positive fundamental updates, including strong ARCALYST growth and raised guidance, were followed by negative price reactions, hinting at a pattern where upbeat news has coincided with short-term pullbacks.
Over the past several months, Kiniksa has reported strong ARCALYST momentum, with Q3 2025 revenue of $180.9M (up 61% year over year) and full-year 2025 ARCALYST revenue of $677.5M. Guidance was raised to $670M–$675M and later to $900M–$920M for 2026. The company also improved profitability and cash, reporting $414.1M in cash and no debt. Despite these positives, shares fell after the October 2025 earnings and January 2026 corporate update, framing today’s simple earnings-date notice against a backdrop of strong fundamentals but cautious trading.
Market Pulse Summary
This announcement sets the timing for Kiniksa’s fourth quarter and full year 2025 results on February 24, 2026 at 8:30 a.m. ET, with a live webcast and replay. It follows prior disclosures of strong ARCALYST growth to $677.5M in 2025 and raised 2026 guidance. Investors may focus on how final reported figures compare to those unaudited metrics, as well as any updates on portfolio execution and cash levels previously cited at $414.1M with no debt.
AI-generated analysis. Not financial advice.
LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
FAQ
When will Kiniksa (KNSA) report Q4 and full year 2025 results?
How can investors join the Kiniksa (KNSA) earnings conference call on February 24, 2026?
Where will the Kiniksa (KNSA) live webcast of the February 24, 2026 results be available?
Will a replay be available after Kiniksa's February 24, 2026 earnings call?
What information is provided to telephone registrants for the Kiniksa (KNSA) call?
Does Kiniksa (KNSA) provide webcast access for those who cannot attend the live call?
